CompletedNCT00261443
This study exists to explore whether the medication Aripiprazole could improve care and understanding. Researchers are trying to understand what the medication Aripiprazole could change in day-to-day care and decision-making.
BipolarityOtherOver 18 Years
- Countries
- Brazil, Bulgaria, Croatia, Czech Republic, France, India, Russian Federation, South Africa, United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- Bipolarity
TerminatedNCT02936466
This study exists to compare options and see whether psychoeducation, a guided learning and support program, offers something meaningfully different. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve sleep, daily rhythms, and longer-term stability.
BipolarityOtherOver 18 Years
- Countries
- France
- Sponsor
- University Hospital, Montpellier
- Condition
- Bipolarity
CompletedNCT02204254
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.
BipolarityOtherFrom 18 Years to 70 Years
- Countries
- France
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Condition
- Bipolarity
CompletedNCT03630822
This study exists to understand how acceptance and commitment therapy, a talking treatment, holds up over time after the earliest research stage. Researchers are trying to understand whether acceptance and commitment therapy, a talking treatment, can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherOver 18 Years
- Countries
- France
- Sponsor
- Assistance Publique Hopitaux De Marseille
- Condition
- Schizophrenia
CompletedNCT00280566
This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.
BipolarityOtherOver 18 Years
- Countries
- Chile, France, Germany, Guatemala, China, India, Italy, Mexico, Russian Federation, Spain, Taiwan, United States, Venezuela
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Condition
- Bipolarity
CompletedNCT03028545
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 80 Years
- Countries
- France
- Sponsor
- Hôpital le Vinatier
- Condition
- Schizophrenia
CompletedNCT04034147
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
BipolarityOtherFrom 18 Years to 65 Years
- Countries
- France
- Sponsor
- Versailles Hospital
- Condition
- Bipolarity
CompletedNCT03249857
This study exists to see whether the medication Sensorimotor can play a useful role in care. Researchers are trying to understand whether the medication Sensorimotor can improve attention, thinking, or day-to-day functioning.
BipolarityOtherFrom 18 Years to 55 Years
- Countries
- France
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
- Condition
- Bipolarity
CompletedNCT01973478
This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.
DepressionOtherFrom 18 Years to 70 Years
- Countries
- France
- Sponsor
- Rennes University Hospital
- Condition
- Depression
CompletedNCT01914393
This study exists to understand how a medication treatment holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.
SchizophreniaOtherFrom 6 Years to 17 Years
- Countries
- Bulgaria, Colombia, France, Hungary, Malaysia, Mexico, Philippines, Poland, United States, Romania, Russian Federation, South Korea, Spain, Ukraine
- Sponsor
- Sumitomo Pharma America, Inc.
- Condition
- Schizophrenia
TerminatedNCT02472483
This study exists to explore whether cognitive behavioural therapy, a structured talking treatment, could improve care and understanding. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.
BipolarityOtherFrom 18 Years to 65 Years
- Countries
- France
- Sponsor
- Centre Hospitalier St Anne
- Condition
- Bipolarity
TerminatedNCT01674010
This study exists to understand how the medication ELND005 holds up over time after the earliest research stage. For people living with Bipolarity, that matters because care needs to work in daily life, not just in theory.
BipolarityOtherFrom 18 Years to 65 Years
- Countries
- Bulgaria, Canada, Czech Republic, France, Poland, Romania, Spain, Turkey, United States
- Sponsor
- OPKO Health, Inc.
- Condition
- Bipolarity
CompletedNCT03162380
This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
BipolarityOtherFrom 18 Years to 65 Years
- Countries
- France
- Sponsor
- University Hospital, Montpellier
- Condition
- Bipolarity
CompletedNCT01710709
This study exists to compare options and see whether the medication OPC-14597 offers something meaningfully different. Researchers are trying to understand whether the medication OPC-14597 can give earlier or clearer feedback during care.
BipolarityOtherFrom 18 Years to 65 Years
- Countries
- Canada, France, Hungary, Japan, Malaysia, Poland, Romania, South Korea, Taiwan, United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- Bipolarity
TerminatedNCT01121536
This study exists to better understand the safety of a therapy or guided support program and how manageable it feels in practice. Researchers are trying to understand how people respond to a therapy or guided support program in practice and what may need to be adjusted.
DepressionOtherFrom 18 Years to 65 Years
- Countries
- Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Hungary, Italy, Poland, Serbia, Slovakia, South Africa, Spain, Ukraine, United States
- Sponsor
- Cephalon
- Condition
- Depression
CompletedNCT02046369
This study exists to understand whether a medication treatment is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.
BipolarityOtherFrom 10 Years to 17 Years
- Countries
- Bulgaria, Colombia, France, Hungary, Mexico, Philippines, Poland, United States, South Korea, Ukraine
- Sponsor
- Sumitomo Pharma America, Inc.
- Condition
- Bipolarity
CompletedNCT01485640
This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.
SchizophreniaOther
- Countries
- Canada, Colombia, Czech Republic, France, India, Lithuania, Romania, Russian Federation, Serbia, Slovakia, South Africa, Ukraine
- Sponsor
- Sumitomo Pharma America, Inc.
- Condition
- Schizophrenia
CompletedNCT01358357
This study exists to understand how the medication Lurasidone holds up over time after the earliest research stage. Researchers are trying to understand how people respond to the medication Lurasidone in practice and what may need to be adjusted.
BipolarityOtherOver 18 Years
- Countries
- Argentina, Australia, Bulgaria, Chile, Croatia, Czech Republic, France, Hungary, Japan, Poland, Russian Federation, Serbia, Slovakia, United States
- Sponsor
- Sumitomo Pharma America, Inc.
- Condition
- Bipolarity
CompletedNCT01575561
This study exists to understand how a medication treatment holds up over time after the earliest research stage. Researchers are trying to understand whether a medication treatment can better prevent setbacks and support longer-term stability.
BipolarityOtherOver 18 Years
- Countries
- Argentina, Bulgaria, Chile, Czech Republic, France, Hungary, Japan, Poland, Russian Federation, Serbia, Slovakia, United States
- Sponsor
- Sumitomo Pharma America, Inc.
- Condition
- Bipolarity
CompletedNCT02642926
This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can better support energy, concentration, and everyday functioning.
BipolarityOtherOver 18 Years
- Countries
- France
- Sponsor
- Brugmann University Hospital
- Condition
- Bipolarity
CompletedNCT01072630
This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand what a therapy or guided support program could change in day-to-day care and decision-making.
DepressionOtherFrom 18 Years to 65 Years
- Countries
- Argentina, Australia, Bulgaria, Canada, France, Poland, South Africa, Spain, Ukraine, United States
- Sponsor
- Cephalon
- Condition
- Depression
CompletedNCT00868959
This study exists to explore whether the medication Patients could improve care and understanding. For people living with Depression, that matters because care needs to work in daily life, not just in theory.
DepressionOtherFrom 18 Years to 75 Years
- Countries
- Canada, Colombia, Czech Republic, France, India, Japan, Lithuania, Peru, Poland, Romania, Russian Federation, Slovakia, South Africa, Ukraine, United States
- Sponsor
- Sumitomo Pharma America, Inc.
- Condition
- Depression
CompletedNCT01689389
This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.
SchizophreniaOtherFrom 18 Years to 130 Years
- Countries
- France
- Sponsor
- AstraZeneca
- Condition
- Schizophrenia
TerminatedNCT01809340
This study exists to compare options and see whether ketamine treatment offers something meaningfully different. Researchers are trying to understand whether ketamine treatment can better prevent setbacks and support longer-term stability.
DepressionOtherFrom 18 Years to 80 Years
- Countries
- Belgium, France, Netherlands, Spain
- Sponsor
- Janssen Research & Development, LLC
- Condition
- Depression
CompletedNCT00490971
This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can improve sleep, daily rhythms, and longer-term stability.
BipolarityOtherFrom 18 Years to 65 Years
- Countries
- Bulgaria, China, Costa Rica, France, Germany, India, Malaysia, Panama, Poland, Romania, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United States
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Condition
- Bipolarity